 |
answer text |
<p>Orkambi, Symkevi and Kaftrio are currently available as treatment options for eligible
National Health Service patients with cystic fibrosis, under the terms of a commercial
agreement reached between NHS England and the manufacturer. This agreement has enabled
the collection of data to inform a full appraisal of these medicines by the National
Institute for Health and Care Excellence (NICE), which is currently underway.</p><p>NICE
published draft guidance on 3 November 2023 which does not recommend Orkambi, Symkevi
and Kaftrio for the treatment of cystic fibrosis. The draft guidance is now subject
to a public consultation and NICE’s committee will carefully consider all evidence
as well as comments received during the consultation in developing its final guidance,
which is expected to be published on 20 March 2024. Patients already receiving these
treatments will have continued access following the publication of NICE’s final guidance,
regardless of the outcome.</p>
|
 |
